Giovanni Lo Re

Medicine & Life Sciences

1. dabrafenib 100%
2. trametinib 99%
3. Renal Cell Carcinoma 91%
4. Nivolumab 72%
5. Italy 70%
6. Castration 70%
7. MDV 3100 62%
8. Prostatic Neoplasms 58%
9. Docetaxel 58%
10. Melanoma 52%
11. Axitinib 50%
12. Sunitinib 43%
13. Prednisone 43%
14. Safety 35%
15. Survival 29%
16. Oxaliplatin 24%
17. Therapeutics 23%
18. Metformin 22%
19. Colonic Neoplasms 19%
20. Interleukin-2 18%
21. Chronotherapy 16%
22. Progression-Free Survival 14%
23. Neoplasm Metastasis 13%
24. Combined Modality Therapy 13%
25. human ERBB2 protein 12%
26. Radiopharmaceuticals 12%
27. Biological Therapy 12%
28. Drug Therapy 12%
29. Fatigue 11%
30. Prostatectomy 10%
31. L-Lactate Dehydrogenase 10%
32. Lymph Node Excision 10%
33. Elderly 10%
34. Bone and Bones 10%
35. Confidence Intervals 10%
36. Fluorouracil 10%
37. Haplotypes 9%
38. Cyclophosphamide 9%
39. Neoplasms 9%
40. Stomach Neoplasms 9%
41. Population Control 8%
42. Brain 8%
43. Febrile Neutropenia 7%
44. Androgen Receptors 6%
45. Cadherins 6%
46. Disease Progression 6%
47. Recurrence 6%
48. Neutropenia 6%
49. Everolimus 5%
50. Hypothyroidism 5%